The predictive algorithm correctly classified 83 out of 86 (97%) patients in the WM group and 33 out of 40 (83%) patients in the MZL group based on the selected markers, including percentages of CD43, FMC7, CD38, CD13, and MFI of CD19, FMC7, CD22, CD27 and CD79b. Here, CD22 is linked to marginal zone lymphoma.